PetMeds® Announces Its Third Fiscal Quarter Financial Results and Its Quarterly Dividend of $0.30 Per Share

  • January 24, 2022
  • Home
  • USA
  • PetMeds® Announces Its Third Fiscal Quarter Financial Results and Its Quarterly Dividend of $0.30 Per Share

DELRAY BEACH, Fla., Jan. 24, 2022 (GLOBE NEWSWIRE) — PetMed Express, Inc. (NASDAQ: PETS) today announced its financial results for the quarter ended December 31, 2021. Net sales for the quarter ended December 31, 2021, were $60.7 million, compared to $65.9 million for the quarter ended December 31, 2020, a decrease of 7.9%. Net sales for the nine months ended December 31, 2021, were $207.4 million, compared to $237.5 million for the nine months ended December 31, 2020, a decrease of 12.7%. Net income was $4.3 million, or $0.21 diluted per share, for the quarter ended December 31, 2021, compared to net income of $7.6 million, or $0.38 diluted per share, for the quarter ended December 31, 2020, a 44% decrease to net income. Net income was $15.0 million, or $0.74 diluted per share, for the nine months ended December 31, 2021, compared to net income of $23.8 million, or $1.18 diluted per share, for the nine months ended December 31, 2020, a 37% decrease to net income. Adjusted EBITDA (1) was $7.6 million, or $0.37 diluted per share, for the quarter ended December 31, 2021, compared to adjusted EBITDA of $11.0 million, or $0.55 diluted per share, for the quarter ended December 31, 2020, a 31% decrease to adjusted EBITDA. Adjusted EBITDA was $24.5 million, or $1.20 diluted per share, for the nine months ended December 31, 2021, compared to adjusted EBITDA of $34.2 million, or $1.70 diluted per share, for the nine months ended December 31, 2020, a 28% decrease to adjusted EBITDA. Our average order size increased from $88 to $89 for the quarters ended December 31, 2020 and 2021, respectively.

“We are executing rapidly against our business transformation of PetMeds across people, process, and product,” said Matt Hulett, CEO and President. “The future of PetMeds is much broader than just a prescription eCommerce company and we expect to show progress in the coming quarters as we develop into a broader expert health and wellness offering.”

The Board of Directors declared a quarterly dividend of $0.30 per share on the Company’s common stock. The dividend will be payable on February 18, 2022, to shareholders of record at the close of business on February 7, 2022. The Company intends to continue to pay regular quarterly dividends; however, the declaration and payment of future dividends is discretionary and will be subject to a determination by the Board of Directors each quarter following its review of the Company’s financial performance.

This afternoon at 4:30 P.M. Eastern Time, the Company will host a conference call to review the quarter’s financial results. To access the call, which is open to the public, please dial (877) 407-0789 (toll free) or (201) 689-8562. We will also provide a link at https://www.1800petmeds.com/investor.html for those who wish to stream the call via webcast. For those unable to participate in the live event, the call will be available for replay from 7:30 P.M. Eastern Time on January 24, 2022, until February 7, 2022, at 11:59 P.M. Eastern Time. To access the replay, call (844) 512-2921 (toll free) or (412) 317-6671 and enter passcode 13726200.

Founded in 1996, PetMed Express is America’s Most Trusted Pet Pharmacy®, delivering prescription and non-prescription pet medications and other health products for dogs, cats, and horses at competitive prices direct to the consumer through its 1-800-PetMeds toll free number and on the Internet through its website at www.petmeds.com.

This press release may contain “forward-looking” statements, as defined in the Private Securities Litigation Reform Act of 1995 or by the Securities and Exchange Commission, that involve a number of risks and uncertainties, including the Company’s ability to meet the objectives included in its business plan. Important factors that could cause results to differ materially from those indicated by such “forward-looking” statements are set forth in Management’s Discussion and Analysis of Financial Condition and Results of Operations in the PetMed Express Annual Report on Form 10-K for the year ended March 31, 2021. The Company’s future results may also be impacted by other risk factors listed from time to time in its SEC filings, including, but not limited to, the Company’s Form 10-Q and its Annual Report on Form 10-K.

For investment relations contact PetMed Express, Inc., Bruce S. Rosenbloom, CFO, 561-526-4444, [email protected].

For media relations contact Butin PR, Mary Eva Tredway, [email protected].

(1) Adjusted EBITDA and adjusted EBITDA per share are non-GAAP financial measures. See “Non-GAAP Financial Measures” for additional information on non-GAAP financial measures and a reconciliation to the most comparable GAAP measures.

PETMED EXPRESS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except for per share data)
         
    December 31,   March 31,
     2021   2021 
ASSETS   (Unaudited)    
         
Current assets:        
Cash and cash equivalents $ 108,911 $ 118,718
Accounts receivable, less allowance for doubtful accounts of $19 and $39, respectively   1,267   2,587
Inventories – finished goods   27,640   34,420
Prepaid expenses and other current assets   3,216   4,503
Prepaid income taxes   1,870   959
Total current assets   142,904   161,187
         
Noncurrent assets:        
Property and equipment, net   24,665   25,450
Intangible assets   860   860
Total noncurrent assets   25,525   26,310
         
Total assets $ 168,429 $ 187,497
         
LIABILITIES AND SHAREHOLDERS’ EQUITY        
         
Current liabilities:        
Accounts payable $ 21,935 $ 39,548
Accrued expenses and other current liabilities   4,330   5,387
Total current liabilities   26,265   44,935
         
Deferred tax liabilities   1,262   1,281
         
Total liabilities   27,527   46,216
         
Commitments and contingencies        
         
Shareholders’ equity:        
Preferred stock, $.001 par value, 5,000 shares authorized; 3 convertible shares issued and outstanding with a liquidation preference of $4 per share   9   9
Common stock, $.001 par value, 40,000 shares authorized; 20,957 and 20,269 shares issued and outstanding, respectively   21   20
Additional paid-in capital   10,151   7,111
Retained earnings   130,721   134,141
         
Total shareholders’ equity   140,902   141,281
         
Total liabilities and shareholders’ equity $ 168,429 $ 187,497
         
PETMED EXPRESS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(In thousands, except for per share amounts) (Unaudited)
                 
    Three Months Ended   Nine Months Ended
    December 31,   December 31,
    2021   2020   2021   2020
                 
Sales $ 60,717 $ 65,896 $ 207,415 $ 237,536
Cost of sales   42,992   46,273   148,736   168,110
                 
Gross profit   17,725   19,623   58,679   69,426
                 
Operating expenses:                
General and administrative   7,541   6,487   22,540   21,050
Advertising   4,327   3,221   15,435   17,385
Depreciation   710   622   2,051   1,791
Total operating expenses   12,578   10,330   40,026   40,226
                 
Income from operations   5,147   9,293   18,653   29,200
                 
Other income:                
Interest income, net   84   73   243   229
Other, net   287   345   741   938
Total other income   371   418   984   1,167
                 
Income before provision for income taxes   5,518   9,711   19,637   30,367
                 
Provision for income taxes   1,261   2,100   4,603   6,576
                 
Net income $ 4,257 $ 7,611 $ 15,034 $ 23,791
                 
Net income per common share:                
Basic $ 0.21 $ 0.38 $ 0.75 $ 1.19
Diluted $ 0.21 $ 0.38 $ 0.74 $ 1.18
                 
Weighted average number of common shares outstanding:          
Basic   20,208   20,094   20,165   20,047
Diluted   20,329   20,104   20,365   20,100
                 
Cash dividends declared per common share $ 0.30 $ 0.28 $ 0.90 $ 0.84
                 
PETMED EXPRESS, INC. AND SUBSIDIARIES  
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS  
(In thousands) (Unaudited)  
   
      Nine Months Ended  
      December 31,  
      2021     2020    
Cash flows from operating activities:            
Net income   $ 15,034   $ 23,791    
Adjustments to reconcile net income to net cash provided by operating activities:            
Depreciation     2,051     1,791    
Share based compensation     3,040     2,294    
Deferred income taxes     (19 )   353    
Bad debt expense     104     84    
(Increase) decrease in operating assets and increase (decrease) in liabilities:            
Accounts receivable     1,216     1,928    
Inventories – finished goods     6,780     (10,281 )  
Prepaid income taxes     (911 )      
Prepaid expenses and other current assets     1,287     (983 )  
Accounts payable     (17,613 )   2,211    
Accrued expenses and other current liabilities     (1,188 )   286    
Income taxes payable         152    
Net cash provided by operating activities     9,781     21,626    
             
Cash flows from investing activities:            
Purchases of property and equipment     (1,266 )   (1,848 )  
Net cash used in investing activities     (1,266 )   (1,848 )  
             
Cash flows from financing activities:            
Dividends paid     (18,322 )   (17,039 )  
Net cash used in financing activities     (18,322 )   (17,039 )  
             
Net (decrease) increase in cash and cash equivalents     (9,807 )   2,739    
Cash and cash equivalents, at beginning of period     118,718     103,762    
             
Cash and cash equivalents, at end of period   $ 108,911   $ 106,501    
             
Supplemental disclosure of cash flow information:            
             
Cash paid for income taxes   $ 5,580   $ 6,356    
             
Dividends payable in accrued expenses   $ 329   $ 174    
             

 

Non-GAAP Financial Measures

To provide investors with additional information regarding our financial results, we have disclosed here and elsewhere in this earnings release adjusted EBITDA and adjusted EBITDA per share, non-GAAP financial measures that we calculate as net income excluding; share-based compensation expense; depreciation and amortization; income tax provision; and interest income (expense). We have provided reconciliations below of adjusted EBITDA to net income and adjusted EBITDA per share to diluted earnings per share, the most directly comparable GAAP financial measures.

We have included adjusted EBITDA and adjusted EBITDA per share in this earnings release because they are key measures used by our management and board of directors to evaluate our operating performance, generate future operating plans and make strategic decisions regarding the allocation of capital. In particular, the exclusion of certain expenses in calculating adjusted EBITDA facilitates operating performance comparability across reporting periods by removing the effect of non-cash expenses. Accordingly, we believe that adjusted EBITDA and adjusted EBITDA per share provide useful information to investors and others in understanding and evaluating our operating results in the same manner as our management and board of directors.

We believe it is useful to exclude non-cash charges, such as, share-based compensation expense and depreciation and amortization from our adjusted EBITDA and adjusted EBITDA per share because the amount of such expenses in any specific period may not directly correlate to the underlying performance of our business operations. We believe it is useful to exclude income tax provision; interest income (expense) which are not components of our core business operations. Adjusted EBITDA and adjusted EBITDA per share has limitations as financial measures, and you should not consider it in isolation or as a substitute for analysis of our results as reported under GAAP. Some of these limitations are:

  • Although depreciation and amortization are non-cash charges, the assets being depreciated and amortized may have to be replaced in the future and adjusted EBITDA and adjusted EBITDA per share does not reflect capital expenditure requirements for such replacements or for new capital expenditures;
  • Adjusted EBITDA and adjusted EBITDA per share does not reflect share-based compensation. Share-based compensation has been, and will continue to be for the foreseeable future, a material recurring expense in our business and an important part of our compensation strategy;
  • Adjusted EBITDA and adjusted EBITDA per share does not reflect interest income (expense), net; or changes in, or cash requirements for, our working capital; and
  • Other companies, including companies in our industry, may calculate adjusted EBITDA and adjusted EBITDA per share differently, which reduces its usefulness as a comparative measure.

Because of these limitations, you should consider adjusted EBITDA and adjusted EBITDA per share alongside other financial performance measures, including various cash flow metrics, net income, net margin, and our other GAAP results. The following table presents a reconciliation of net income to adjusted EBITDA and adjusted EBITDA per share for each of the periods indicated:

Reconciliation of Non-GAAP Measures
PetMed Express, Inc.
(Unaudited)
 
  Three Months Ended     Nine Months Ended    
  December 31, December 31, $ % December 31, December 31, $ %
($ in thousands, except percentages)   2021     2020   Change Change   2021     2020   Change Change
                 
Consolidated Reconciliation of GAAP Net Income to Adjusted EBITDA:
                 
Net income $ 4,257   $ 7,611   $ (3,354 ) -44 % $ 15,034   $ 23,791   $ (8,757 ) -37 %
                 
Add (subtract):                
Share-based compensation $ 1,440   $ 782   $ 658   84 % $ 3,040   $ 2,294   $ 746   33 %
Income Taxes $ 1,261   $ 2,100   $ (839 ) -40 % $ 4,603   $ 6,576   $ (1,973 ) -30 %
Depreciation $ 710   $ 622   $ 88   14 % $ 2,051   $ 1,791   $ 260   15 %
Interest Income/Expense $ (84 ) $ (73 ) $ (11 ) 15 % $ (243 ) $ (229 ) $ (14 ) 6 %
                 
Adjusted EBITDA $ 7,584   $ 11,042   $ (3,458 ) -31 % $ 24,485   $ 34,223   $ (9,738 ) -28 %
                 

 

 
  Three Months Ended     Nine Months Ended    
($ in thousands, except percentages December 31, December 31, $ % December 31, December 31, $ %
and per share amounts)   2021     2020   Change Change   2021     2020   Change Change
                 
Consolidated Reconciliation of GAAP Net Income Per Share to Adjusted EBITDA per share:
                 
Net income per share, diluted $ 0.21   $ 0.38   $ (0.17 ) -45 % $ 0.74   $ 1.18   $ (0.45 ) -38 %
                 
Add (subtract):                
Share-based compensation $ 0.07   $ 0.04   $ 0.03   82 % $ 0.15   $ 0.11   $ 0.04   31 %
Income Taxes $ 0.06   $ 0.10   $ (0.04 ) -41 % $ 0.22   $ 0.33   $ (0.10 ) -31 %
Depreciation $ 0.03   $ 0.03   $ 0.00   13 % $ 0.10   $ 0.09   $ 0.01   13 %
Interest Income/Expense $ (0.00 ) $ (0.00 ) $ (0.00 ) 14 % $ (0.01 ) $ (0.01 ) $ 0.00   5 %
                 
Adjusted EBITDA Per Share $ 0.37   $ 0.55   $ (0.18 ) -32 % $ 1.20   $ 1.70   $ (0.50 ) -29 %
                 


Wall St Business News, Latest and Up-to-date Business Stories from Newsmakers of Tomorrow